Stock AnalizEstablishment Labs Holdings Inc. ESTA
Industrial Specialties · IPO 2018 · data as of November 13, 2026
Establishment Labs Holdings Inc. (ESTA) is a healthcare company listed in the US with a market value of about $2.1B. In the twelve months to September 30, 2026 it had revenue of $264M and net income of -$38M, a net margin of -14.6%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 20% a year, a 5-year average ROIC of -20%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 94% below the current price.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $264M | $211M | $166M | $165M | $162M | $127M | $85M | $90M | $61M | $35M |
| Net income | -$38M | -$51M | -$85M | -$79M | -$75M | -$41M | -$38M | -$38M | -$21M | -$35M |
| Free cash flow | -$22M | -$57M | -$65M | -$96M | -$55M | -$30M | -$15M | -$36M | -$36M | -$33M |
| EPS (diluted) | $-1.27 | $-1.72 | $-3.00 | $-3.07 | $-3.08 | $-1.72 | $-1.63 | $-1.86 | $-1.22 | $-3.41 |
| Net margin | -14.6% | -24.2% | -50.9% | -47.5% | -46.5% | -32.5% | -45.0% | -42.6% | -34.5% | -100.6% |
| ROIC | — | -12.5% | -17.9% | -30.8% | -18.3% | -18.9% | -17.3% | -27.9% | -20.5% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $98.00, 39% above the current price; targets range from $90.00 to $105.00; the consensus rating is “Strong buy”; expected EPS is $-1.34 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Establishment Labs stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 94% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Establishment Labs pay a dividend?
Not currently.
Is Establishment Labs a good stock to buy?
We do not give buy or sell advice. Establishment Labs scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.